Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Colorcon
AstraZeneca
Harvard Business School
Boehringer Ingelheim

Last Updated: November 17, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for RAF-265

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug RAF-265?

RAF-265 is an investigational drug.

There have been 216 clinical trials for RAF-265. The most recent clinical trial was a Phase 3 trial, which was initiated on January 28th 2016.

The most common disease conditions in clinical trials are Melanoma, Colorectal Neoplasms, and Carcinoma. The leading clinical trial sponsors are National Cancer Institute (NCI), Bayer, and Novartis Pharmaceuticals.

There are thirty-six US patents protecting this investigational drug and five hundred and seventy-three international patents.

Recent Clinical Trials for RAF-265
TitleSponsorPhase
MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable Neuroblastoma RAS (NRAS) MelanomaHospices Civils de LyonN/A
Cobimetinib for BRAF-wild-type HistiocytosesAssistance Publique - Hôpitaux de ParisPhase 3
Atropine for Children Myopia Progression StudyShanghai General Hospital, Shanghai Jiao Tong University School of MedicinePhase 4

See all RAF-265 clinical trials

Clinical Trial Summary for RAF-265

Top disease conditions for RAF-265
Top clinical trial sponsors for RAF-265

See all RAF-265 clinical trials

US Patents for RAF-265

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
RAF-265   Start Trial Low, immune enhancing, dose mtor inhibitors and uses thereof Novartis AG (Basel, CH)   Start Trial
RAF-265   Start Trial Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA)   Start Trial
RAF-265   Start Trial Formylated N-heterocyclic derivatives as FGFR4 inhibitors NOVARTIS AG (Basel, CH)   Start Trial
RAF-265   Start Trial Methods of treating hemoglobinopathies Duke University (Durham, NC)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for RAF-265

Drugname Country Document Number Estimated Expiration Related US Patent
RAF-265 Australia 2014348657 2033-11-13   Start Trial
RAF-265 Australia 2017245411 2033-11-13   Start Trial
RAF-265 Canada 2929181 2033-11-13   Start Trial
RAF-265 China 105899232 2033-11-13   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
AstraZeneca
Johnson and Johnson
Mallinckrodt
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.